At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
bortezomibdrug
Likely dose
Bortezomib IV (specific dose not provided in protocol)AI-extracted
Key inclusion· 7
- ✓Histologically confirmed BAC or adenocarcinoma with BAC features at stage IIIB or IV
- ✓Measurable disease ≥20 mm by conventional imaging or ≥10 mm by spiral CT
- ✓ECOG performance status 0-2
- ✓Life expectancy >3 months
Key exclusion· 7
- ✕Unstable brain metastases (stable for <1 month after radiotherapy or surgery)
- ✕More than 1 prior chemotherapy regimen for advanced BAC
- ✕Peripheral neuropathy grade 2 or higher
- ✕Prior bortezomib therapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Bortezomib (PS-341) for Patients With Advanced Bronchiolo-Alveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features
In Brief
A Phase 2 clinical trial evaluating bortezomib for Adenocarcinoma of the Lung and 5 related conditions. Completed, enrolled 42 participants across 1 site.
Detailed Summary
This phase II trial is studying how well bortezomib works in treating patients with stage IIIB or stage IV lung cancer. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2005
First PostedJul 2005
Primary CompletionDec 2010
TodayJul 2026
First PostedJul 11, 2005
Enrollment StartJun 1, 2005
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 21.0 years ago
Interventions
bortezomibdrug
Given IV